Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) patented drug-delivery platform, DehydraTECH, has exhibited continued success in recent animal lab tests by delivering cannabinoids to the bloodstream faster than conventional cannabinoid formulations (http://nnw.fm/fsKW4). A recent article discussing the company reads, “Lab tests and actual licensed use in the cannabis industry have proved that DehydraTECH’s long-chain fatty acid (“LCFA”) formulation is able to deliver cannabinoids faster than formulations with medium-chain triglyceride (“MCT”) oils, such as coconut oil. DehydraTECH also offers the most advanced flavor and aroma-profile masking techniques in the industry. The groundbreaking technology could negate the need for artificial chemical masking agents or flavoring agents/sweeteners that mask the bitter flavors and aromas of cannabis. . . . Over the entire 60 minutes of the study, the DehydraTECH LCFA formulation delivered a CBD blood concentration level that was 334 percent higher than the level identified in animals that received the MCT oil formulation. The lab tests on animals compared how quickly a DehydraTECH formulation containing LCFA could deliver cannabinoids to the bloodstream, as compared to a concentration-matched conventional industry cannabinoid edible formulation with MCT oil. Coconut oil is commonly used due to its luxurious taste and mouth-feel, which can hide unpleasant cannabis flavors.”
To view the full article, visit: http://nnw.fm/6sIqz
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its disruptive delivery technology, which promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com